Summary
Alzheimer’s disease (AD) is an age-related neurodegenerative disease with two major hallmarks: extracellular amyloid plaques made of amyloid-β (Aβ) and intracellular neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated tau. The number of NFTs correlates positively with the severity of dementia in AD patients. However, there is still no efficient therapy available for AD treatment and prevention so far. A deeper understanding of AD pathogenesis has identified novel strategies for the generation of specific therapies over the past few decades. Several studies have suggested that the prion-like seeding and spreading of tau pathology in the brain may be a key driver of AD. Tau protein is considered as a promising candidate target for the development of therapeutic interventions due to its considerable pathological role in a variety of neurodegenerative disorders. Abnormal tau hyperphosphorylation plays a detrimental pathological role, eventually leading to neurodegeneration. In the present review, we describe the recent research progresses in the pathological mechanisms of tau protein in AD and briefly discuss tau-based therapeutic strategies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem, 1986,261(13):6084–6089
Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology, 1992,42(3 Pt 1):631–639
Riley KP, Snowdon DA, Markesbery WR. Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol, 2002,51(5):567–577
Kopke E, Tung YC, Shaikh S, et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem, 1993,268(32):24 374–24 384
Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA, 1986,83(13): 4913–4917
Alonso AC, Zaidi T, Grundke-Iqbal I, et al. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA, 1994,91(12): 5562–5566
Alonso A, Zaidi T, Novak M, et al. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA, 2001,98(12): 6923–6928
Braak H, Del Tredici K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol, 2011,121(2):171–181
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, 1991, 82(4):239–259
Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging, 1995, 16(3):271–278
Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging, 1999,20(6): 573–579
Ahmed Z, Cooper J, Murray TK, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol, 2014,127(5): 667–683
Kumar H, Udgaonkar JB. Mechanistic approaches to understand the prion-like propagation of aggregates of the human tau protein. Biochim Biophys Acta Proteins Proteom, 2019,1867(10):922–932
Colin M, Dujardin S, Schraen-Maschke S, et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol, 2020,139(1): 3–25
Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci, 2017,40:189–210
Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron, 1989,3(4): 519–526
Iqbal K, Alonso Adel C, Chen S, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta, 2005,1739(2–3): 198–210
Kosik KS, Orecchio LD, Bakalis S, et al. Developmentally regulated expression of specific tau sequences. Neuron, 1989,2(4): 1389–1397
Takuma H, Arawaka S, Mori H. Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res, 2003,142(2):121–127
Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener, 2009,4:13
Mukrasch MD, Bibow S, Korukottu J, et al. Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol, 2009,7(2): e34
Papasozomenos SC, Binder LI. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton, 1987,8(3):210–226
Trojanowski JQ, Schuck T, Schmidt ML, et al. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem, 1989,37(2): 209–215
Iqbal K, Liu F, Gong CX. Recent developments with tau-based drug discovery. Expert Opin Drug Discov, 2018,13(5):399–410
Chu D, Liu F. Pathological Changes of Tau Related to Alzheimer’s Disease. ACS Chem Neurosci, 2019,10(2): 931–944
Chidambaram H, Chinnathambi S. G-Protein Coupled Receptors and Tau-different Roles in Alzheimer’s Disease. Neuroscience, 2020,438:198–214
Neddens J, Temmel M, Flunkert S, et al. Phosphorylation of different tau sites during progression of Alzheimer’s disease. Acta Neuropathol Commun, 2018,6(1): 52
Avila J, Lucas JJ, Perez M, et al. Role of tau protein in both physiological and pathological conditions. Physiol Rev, 2004,84(2): 361–384
LaPointe NE, Morfini G, Pigino G, et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res, 2009,87(2): 440–451
Xia D, Li C, Gotz J. Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. Biochim Biophys Acta, 2015,1852(5): 913–924
Alonso AC, Grundke-Iqbal I, Iqbal K. Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med, 1996,2(7):783–787
Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci, 2007, 25(1):59–68
Pei JJ, Grundke-Iqbal I, Iqbal K, et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer’s disease neurofibrillary degeneration. Brain Res, 1998,797(2): 267–277
Jin N, Yin X, Yu D, et al. Truncation and activation of GSK-3beta by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer’s disease. Sci Rep, 2015,5:8187
Jin N, Yin X, Gu J, et al. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE. J Biol Chem, 2015,290(24): 15 219–15 237
Llorach-Pares L, Nonell-Canals A, Avila C, et al. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer’s Disease: A Computational Study. Mar Drugs, 2018,16(10): 386
Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med, 2009,15(3):112–119
Wu XL, Pina-Crespo J, Zhang YW, et al. Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer’s Disease. Chin Med J (Engl), 2017,130(24): 2978–2990
Reimer L, Betzer C, Kofoed RH, et al. PKR kinase directly regulates tau expression and Alzheimer’s disease-related tau phosphorylation. Brain Pathol, 2020,27:1–17
Muralidar S, Ambi SV, Sekaran S, et al. Role of tau protein in Alzheimer’s disease: The prime pathological player. Int J Biol Macromol, 2020,163:1599–1617
Liu F, Iqbal K, Grundke-Iqbal I, et al. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett, 2002,530(1–3): 209–214
Woods YL, Cohen P, Becker W, et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J, 2001,355(Pt 3):609–615
Liu F, Liang Z, Wegiel J, et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J, 2008,22(9): 3224–3233
Singh TJ, Zaidi T, Grundke-Iqbal I, et al. Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett, 1995,358(1): 4–8
Sengupta A, Wu Q, Grundke-Iqbal I, et al. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem, 1997,167(1–2): 99–105
Gong CX, Liu F, Wu G, et al. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. J Neurochem, 2004,88(2): 298–310
Liu F, Grundke-Iqbal I, Iqbal K, et al. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci, 2005,22(8): 1942–1950
Wasik U, Schneider G, Mietelska-Porowska A, et al. Calcyclin binding protein and Siah-1 interacting protein in Alzheimer’s disease pathology: neuronal localization and possible function. Neurobiol Aging, 2013,34(5): 1380–1388
Diaz-Hernandez M, Gomez-Ramos A, Rubio A, et al. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem, 2010,285(42): 32 539–32 548
Liu F, Iqbal K, Grundke-Iqbal I, et al. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer’s disease. J Biol Chem, 2005,280(3): 1790–1796
Liang Z, Liu F, Iqbal K, et al. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis, 2008,13(3): 295–302
Qian W, Yin X, Hu W, et al. Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer’s disease. J Alzheimers Dis, 2011, 23(4):617–627
Gong CX, Shaikh S, Wang JZ, et al. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem, 1995, 65(2):732–738
Gong CX, Singh TJ, Grundke-Iqbal I, et al. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem, 1993,61(3): 921–927
Wang Y, Yang R, Gu J, et al. Cross talk between PI3K-AKT-GSK-3beta and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging, 2015,36(1): 188–200
Qian W, Shi J, Yin X, et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis, 2010,19(4): 1221–1229
Chu D, Tan J, Xie S, et al. GSK-3beta is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner. J Alzheimers Dis, 2016,49(2): 365–375
Zilka N, Filipcik P, Koson P, et al. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett, 2006, 580(15):3582–3588
Hasegawa M, Morishima-Kawashima M, Takio K, et al. Protein sequence and mass spectrometric analyses of tau in the Alzheimer’s disease brain. J Biol Chem, 1992,267(24): 17 047–17 054
Yang LS, Ksiezak-Reding H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur J Biochem, 1995,233(1):9–17
Basurto-Islas G, Gu JH, Tung YC, et al. Mechanism of Tau Hyperphosphorylation Involving Lysosomal Enzyme Asparagine Endopeptidase in a Mouse Model of Brain Ischemia. J Alzheimer Dis, 2018,63(2): 821–833
Gamblin TC, Chen F, Zambrano A, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proc Natl Acad Sci USA, 2003,100(17): 10 032–10 037
Zhang Z, Song M, Liu X, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat Med, 2014, 20(11):1254–1262
Wischik CM, Novak M, Thogersen HC, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA, 1988,85(12): 4506–4510
de Calignon A, Fox LM, Pitstick R, et al. Caspase activation precedes and leads to tangles. Nature, 2010, 464(7292):1201–1204
Zhou Y, Shi J, Chu D, et al. Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease. Front Aging Neurosci, 2018,10:27
Li L, Jiang Y, Hu W, et al. Pathological Alterations of Tau in Alzheimer’s Disease and 3xTg-AD Mouse Brains. Mol Neurobiol, 2019,56(9): 6168–6183
Yin H, Kuret J. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett, 2006,580(1):211–215
Berry RW, Abraha A, Lagalwar S, et al. Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry, 2003,42(27): 8325–8331
Gu J, Xu W, Jin N, et al. Truncation of Tau selectively facilitates its pathological activities. J Biol Chem, 2020,295(40): 13 812–13 828
Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol, 2017,133(5):665–704
Jadhav S, Katina S, Kovac A, et al. Truncated tau deregulates synaptic markers in rat model for human tauopathy. Front Cell Neurosci, 2015,9:24
Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron, 2010,67(6): 953–966
Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun, 2011,2:252
Cook C, Stankowski JN, Carlomagno Y, et al. Acetylation: a new key to unlock tau’s role in neurodegeneration. Alzheimers Res Ther, 2014,6(3): 29
Tracy T, Claiborn KC, Gan L. Regulation of Tau Homeostasis and Toxicity by Acetylation. Adv Exp Med Biol, 2019,1184:47–55
Cohen TJ, Constance BH, Hwang AW, et al. Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation. PLoS One, 2016,11(7): e0158470
Julien C, Tremblay C, Emond V, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol, 2009,68(1): 48–58
Lattanzio F, Carboni L, Carretta D, et al. Treatment with the neurotoxic Abeta (25–35) peptide modulates the expression of neuroprotective factors Pin1, Sirtuin 1, and brain-derived neurotrophic factor in SH-SY5Y human neuroblastoma cells. Exp Toxicol Pathol, 2016, 68(5):271–276
Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem, 1997,272(14): 9308–9315
Gao Y, Wells L, Comer FI, et al. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem, 2001,276(13): 9838–9845
Hart GW, Kreppel LK, Comer FI, et al. O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization. Glycobiology, 1996,6(7): 711–716
Haltiwanger RS, Blomberg MA, Hart GW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine: polypeptide beta-N-acetylglucosaminyltransferase. J Biol Chem, 1992, 267(13):9005–9013
Liu F, Iqbal K, Grundke-Iqbal I, et al. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA, 2004,101(29): 10 804–10 809
Arnold CS, Johnson GV, Cole RN, et al. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem, 1996, 271(46):28741–28744
Liu F, Shi J, Tanimukai H, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain, 2009,132(Pt 7):1820–1832
Gu J, Jin N, Ma D, et al. Calpain I Activation Causes GLUT3 Proteolysis and Downregulation of O-GlcNAcylation in Alzheimer’s Disease Brain. J Alzheimers Dis, 2018,62(4): 1737–1746
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem, 1998, 67: 425–479
Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans, 2009,37(Pt 5):937–953
Petrucelli L, Dickson D, Kehoe K, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet, 2004,13(7): 703–714
Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem, 2005,94(1):192–203
Mori H, Kondo J, Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science, 1987,235(4796):1641–1644
Kuzuhara S, Mori H, Izumiyama N, et al. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol, 1988, 75(4):345–353
Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer’s disease. J Neurochem, 2000,75(1):436–439
Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol, 1998,143(7):1883–1898
Cripps D, Thomas SN, Jeng Y, et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem, 2006,281(16): 10 825–10 838
Kontaxi C, Piccardo P, Gill AC. Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer’s Disease and Related Tauopathies. Front Mol Biosci, 2017,4:56
Chu TT, Gao N, Li QQ, et al. Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation. Cell Chem Biol, 2016, 23(4):453–461
Schweers O, Schonbrunn-Hanebeck E, Marx A, et al. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J Biol Chem, 1994,269(39): 24 290–24 297
von Bergen M, Friedhoff P, Biernat J, et al. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA, 2000, 97(10):5129–5134
Liu K, Liu Y, Li L, et al. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. Biochim Biophys Acta, 2016,1862(2): 192–201
Necula M, Kuret J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem, 2004,279(48):49 694–49 703
Quinn JP, Corbett NJ, Kellett KAB, et al. Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers. J Alzheimers Dis, 2018,63(1): 13–33
Jeganathan S, von Bergen M, Brutlach H, et al. Global hairpin folding of tau in solution. Biochemistry, 2006,45(7): 2283–2293
Ferreon JC, Jain A, Choi KJ, et al. Acetylation Disfavors Tau Phase Separation. Int J Mol Sci, 2018,19(5): 1360
Yuzwa SA, Cheung AH, Okon M, et al. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. J Mol Biol, 2014,426(8): 1736–1752
Reynolds MR, Berry RW, Binder LI. Site-specific nitration differentially influences tau assembly in vitro. Biochemistry, 2005,44(42):13 997–14 009
Funk KE, Thomas SN, Schafer KN, et al. Lysine methylation is an endogenous post-translational modification of tau protein in human brain and a modulator of aggregation propensity. Biochem J, 2014, 462(1):77–88
Yoshitake J, Soeda Y, Ida T, et al. Modification of Tau by 8-Nitroguanosine 3′,5′-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION. J Biol Chem, 2016,291(43): 22 714–22 720
Luo HB, Xia YY, Shu XJ, et al. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci USA, 2014,111(46): 16 586–16 591
Guru KrishnaKumar V, Baweja L, Ralhan K, et al. Carbamylation promotes amyloidogenesis and induces structural changes in Tau-core hexapeptide fibrils. Biochim Biophys Acta Gen Subj, 2018,1862(12): 2590–2604
Rizzu P, Van Swieten JC, Joosse M, et al. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet, 1999,64(2): 414–421
Alonso Adel C, Mederlyova A, Novak M, et al. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem, 2004,279(33): 34 873–34 881
Lu M, Kosik KS. Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol Biol Cell, 2001,12(1):171–184
Adams SJ, DeTure MA, McBride M, et al. Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One, 2010,55(5): e10810
Mudher A, Colin M, Dujardin S, et al. What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathol Commun, 2017,5(1):99
Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci, 2016,17(1):5–21
Giustiniani J, Guillemeau K, Dounane O, et al. The FK506-binding protein FKBP52 in vitro induces aggregation of truncated Tau forms with prion-like behavior. FASEB J, 2015,29(8): 3171–3181
Wischik CM, Schelter BO, Wischik DJ, et al. Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development. J Alzheimers Dis, 2018,62(3): 1287–1303
Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci, 2001,24:1121–1159
Mamun AA, Uddin MS, Mathew B, et al. Toxic tau: structural origins of tau aggregation in Alzheimer’s disease. Neural Regen Res, 2020,15(8): 1417–1420
Holmes BB, DeVos SL, Kfoury N, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA, 2013,110(33): E3138–3147
Falcon B, Cavallini A, Angers R, et al. Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem, 2015,290(2): 1049–1065
Maiza A, Chantepie S, Vera C, et al. The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Lett, 2018,592(23): 3806–3818
Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem, 2009,284(19):12 845–12 852
Shafiei SS, Guerrero-Munoz MJ, Castillo-Carranza DL. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front Aging Neurosci, 2017, 9: 83
Telling GC, Parchi P, DeArmond SJ, et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science, 1996,274(5295): 2079–2082
Dujardin S, Commins C, Lathuiliere A, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease. Nat Med, 2020,26(8): 1256–1263
Hu W, Zhang X, Tung YC, et al. Hyperphosphorylation determines both the spread and the morphology of tau pathology. Alzheimers Dement, 2016,12(10): 1066–1077
Miao J, Shi R, Li L, et al. Pathological Tau from Alzheimer’s Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo. Front Aging Neurosci, 2019,11:34
Demaegd K, Schymkowitz J, Rousseau F. Transcellular Spreading of Tau in Tauopathies. Chembiochem, 2018, 19(23):2424–2432
Brunello CA, Merezhko M, Uronen RL, et al. Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci, 2020,77(9): 1721–1744
Ittner LM, Gotz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci, 2011,12(2):65–72
Ke YD, Suchowerska AK, van der Hoven J, et al. Lessons from tau-deficient mice. Int J Alzheimers Dis, 2012,2012:873 270
Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol, 2018,14(7):399–415
Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet, 2015,16(9):543–552
Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov, 2015,14(12):843–856
Santa-Maria I, Alaniz ME, Renwick N, et al. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest, 2015,125(2): 681–686
Banzhaf-Strathmann J, Benito E, May S, et al. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J, 2014,33(15): 1667–1680
Smith PY, Hernandez-Rapp J, Jolivette F, et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet, 2015,24(23):6721–6735
Liu W, Zhao J, Lu G. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer’s disease. Biochem Biophys Res Commun, 2016,478(2):852–857
Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci, 2017, 20(4):497–499
Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet, 2016,388(10063): 3017–3026
Jadhav S, Avila J, Scholl M, et al. A walk through tau therapeutic strategies. Acta Neuropathol Commun, 2019,7(1): 22
Noble W, Jimenez-Sanchez M, Perez-Nievas BG, et al. Considerations for future tau-targeted therapeutics: can they deliver? Expert Opin Drug Discov, 2020, 15(3):265–267
Levenson JM, Schroeter S, Carroll JC, et al. NPT088 reduces both amyloid-beta and tau pathologies in transgenic mice. Alzheimers Dement (N Y), 2016,2(3): 141–155
Seidler PM, Boyer DR, Rodriguez JA, et al. Structure-based inhibitors of tau aggregation. Nat Chem, 2018, 10(2):170–176
Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature, 2013,501(7465):45–51
Pooler AM, Polydoro M, Wegmann S, et al. Propagation of tau pathology in Alzheimer’s disease: identification of novel therapeutic targets. Alzheimers Res Ther, 2013,5(5): 49
Bakota L, Brandt R. Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease. Drugs, 2016,76(3): 301–313
Medina M. An Overview on the Clinical Development of Tau-Based Therapeutics. Int J Mol Sci, 2018,19(4):1160
Brunden KR, Zhang B, Carroll J, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci, 2010,30(41): 13 861–13 866
Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci, 2012,32(11): 3601–3611
Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol, 2019,18(6): 549–558
Dai CL, Chen X, Kazim SF, et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna), 2015,122(4): 607–617
Dai CL, Tung YC, Liu F, et al. Tau passive immunization inhibits not only tau but also Abeta pathology. Alzheimers Res Ther, 2017,9(1): 1
Dai CL, Hu W, Tung YC, et al. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 x Tg-AD mice. Alzheimers Res Ther, 2018,10(1): 13
Flach K, Hilbrich I, Schiffmann A, et al. Tau oligomers impair artificial membrane integrity and cellular viability. J Biol Chem, 2012,287(52): 43 223–43 233
Guerrero-Munoz MJ, Gerson J, Castillo-Carranza DL. Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease. Front Cell Neurosci, 2015,9:464
Gerson JE, Sengupta U, Kayed R. Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. Methods Mol Biol, 2017, 1523: 141–157
Author information
Authors and Affiliations
Corresponding author
Additional information
This project was supported by National Natural Science Foundation of China (No. 31870772).
Conflict of Interest Statement
The author declares there is no conflict of interest.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gu, Jl., Liu, F. Tau in Alzheimer’s Disease: Pathological Alterations and an Attractive Therapeutic Target. CURR MED SCI 40, 1009–1021 (2020). https://doi.org/10.1007/s11596-020-2282-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-020-2282-1